Albert Do, MD, MPH
Assistant Professor AdjunctCards
About
Research
Publications
2024
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do A, Zahrawi F, Mehal W. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nature Reviews Drug Discovery 2024, 1-19. PMID: 39609545, DOI: 10.1038/s41573-024-01084-2.Peer-Reviewed Original ResearchSide effect profileTrial end pointsCombination of therapeuticsReverse many aspectsFatty acid synthase inhibitorGenetic susceptibility factorsPlacebo responseEffect profileFibrosis reversalTreated patientsClinical studiesLiver inflammationSynthase inhibitorLiver diseaseTherapeutic approachesClinical useEnd pointsSteatotic liver diseaseTherapeutic landscapeMetabolic environmentHepatocyte deathSusceptibility factorsChronic overnutritionGlobal epidemicLiverChapter 6 Clinical diagnosis and evaluation pathway
Lam R, Banini B, Do A, Lim J. Chapter 6 Clinical diagnosis and evaluation pathway. 2024, 77-100. DOI: 10.1016/b978-0-323-99649-5.00003-0.Peer-Reviewed Original Research
2023
S1581 Assessing the Effectiveness of Incorporating Weight Management Treatments Into a Fatty Liver Disease Program
Do A, Ilagan-Ying Y, Deng Y, Banini B, Lim J, Mehal W. S1581 Assessing the Effectiveness of Incorporating Weight Management Treatments Into a Fatty Liver Disease Program. The American Journal Of Gastroenterology 2023, 118: s1193-s1194. DOI: 10.14309/01.ajg.0000955964.73046.7b.Peer-Reviewed Original ResearchScreening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ilagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseLiver diseaseCommon chronic liver diseaseNonalcoholic fatty liver diseaseCurrent expert guidelinesHigh-risk patientsChronic liver diseaseSteatotic liver diseaseClinical practice implicationsHepatic decompensationLiver biopsySociety guidelinesSpecialty referralsNovel therapiesExpert guidelinesLiver cancerDisease awarenessObesity epidemicSerum indicesClinical practiceScreening toolDiseaseDiagnosisExercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Chen G, Banini B, Do A, Gunderson C, Zaman S, Lim J. Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Genes 2023, 14: 1811. PMID: 37761951, PMCID: PMC10531443, DOI: 10.3390/genes14091811.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseEffects of exerciseFatty liver diseaseHistological outcomesLiver histologyLiver diseaseClinical trialsHistological endpointsSystematic reviewSignificant histopathological improvementNAFLD activity scoreImpact of exerciseIndependent effectsRandom-effects modelSystematic literature searchHistopathological improvementExercise interventionActivity scoreClinical endpointsPooled estimatesMeta-AnalysisTotal participantsLiterature searchComparison groupSa1547 IS TISSUE THE ISSUE? USE AND UTILITY OF LIVER BIOPSY IN A DEDICATED FATTY LIVER DISEASE CLINIC INCORPORATING METABOLIC HEALTH CARE
Ilagan-Ying Y, Tseng R, Valido K, Bollinger B, Kelly M, Do A. Sa1547 IS TISSUE THE ISSUE? USE AND UTILITY OF LIVER BIOPSY IN A DEDICATED FATTY LIVER DISEASE CLINIC INCORPORATING METABOLIC HEALTH CARE. Gastroenterology 2023, 164: s-1286-s-1287. DOI: 10.1016/s0016-5085(23)03992-6.Peer-Reviewed Original ResearchLean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI
Do A, Lim J. Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI. Hepatology 2023, 78: 6-7. PMID: 36896961, DOI: 10.1097/hep.0000000000000360.Peer-Reviewed Original ResearchBroadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity Medicine
Do A, Xu J. Broadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity Medicine. Digestive Diseases And Sciences 2023, 68: 725-728. PMID: 36670325, DOI: 10.1007/s10620-023-07827-2.Peer-Reviewed Original Research
2022
The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review
Chen G, Banini B, Do A, Lim J. The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review. Clinical And Molecular Hepatology 2022, 29: s319-s332. PMID: 36517000, PMCID: PMC10029942, DOI: 10.3350/cmh.2022.0366.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseHepatic steatosisLiver fibrosisLiver diseaseHistological endpointsIndependent effectsSystematic reviewNon-randomized interventional studyMagnetic resonance imaging-based techniquesAdditional large RCTsChronic liver diseaseSignificant histological improvementEffects of exerciseClinical outcome endpointsSystematic literature searchHistological improvementExercise interventionHepatocyte ballooningOriginal research studiesLarge RCTsOutcome endpointsInterventional studyOutcomes of Patients with Opioid-Related Diagnoses in Acute Coronary Syndrome: a National Inpatient Sample-Based Analysis
Kim Y, Pacor J, Do A, Brennan J, Fiellin D, Edelman E. Outcomes of Patients with Opioid-Related Diagnoses in Acute Coronary Syndrome: a National Inpatient Sample-Based Analysis. Journal Of General Internal Medicine 2022, 38: 563-570. PMID: 36376632, PMCID: PMC9971420, DOI: 10.1007/s11606-022-07399-3.Peer-Reviewed Original ResearchConceptsOpioid-related diagnosesPercutaneous coronary interventionCardiac arrestHospital mortalityCoronary syndromeNational Inpatient Sample databaseManagement of ACSRisk of ACSCardiovascular risk factorsOutcomes of patientsAcute coronary syndromeProportion of patientsMultivariable logistic regressionNational Inpatient SampleHospital cardiac arrestRisk of mortalityBackgroundAcute coronary syndromeOutcomes of interestT-testStudent's t-testPrimary independent variableHospital outcomesACS managementCoronary interventionOpioid use
Clinical Trials
Current Trials
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)
HIC ID2000027577RoleSub InvestigatorPrimary Completion Date11/01/2022Recruiting ParticipantsGenderBothAge18 years - 75 years
Academic Achievements & Community Involvement
News
News
- May 31, 2022Source: Healio
Surge in alcohol-related disease during pandemic reveals unmet need for treatment
- September 25, 2021Source: Eat This! Not That!
Warning Signs You're Becoming Obese
- May 10, 2021Source: Everyday Health
Can You Lose Weight by Drinking Water?
- April 12, 2021
Meet Yale Internal Medicine: Albert Do, MD, MPH, Assistant Professor of Medicine (Digestive Diseases)